Effect of Thyroid Hormones on AT1R MRNA Levels in HEK 293 Cells: Implications for Early-Onset Hypertension in Children Born of Preeclamptic Women by Eddins, Amanda
Columbus State University 
CSU ePress 
Theses and Dissertations Student Publications 
2008 
Effect of Thyroid Hormones on AT1R MRNA Levels in HEK 293 
Cells: Implications for Early-Onset Hypertension in Children Born 
of Preeclamptic Women 
Amanda Eddins 
Columbus State University 
Follow this and additional works at: https://csuepress.columbusstate.edu/theses_dissertations 
 Part of the Biology Commons 
Recommended Citation 
Eddins, Amanda, "Effect of Thyroid Hormones on AT1R MRNA Levels in HEK 293 Cells: Implications for 
Early-Onset Hypertension in Children Born of Preeclamptic Women" (2008). Theses and Dissertations. 
122. 
https://csuepress.columbusstate.edu/theses_dissertations/122 
This Thesis is brought to you for free and open access by the Student Publications at CSU ePress. It has been 
accepted for inclusion in Theses and Dissertations by an authorized administrator of CSU ePress. 
EFFECT OF THYROID HORMONES ON ATIRMRNA LEVELS
IN HEK 293 CELLS^IMPtlCATIONS FOR EARLY-ONSET
HYPERTENSION IN CHILDREN BORN OF PREEGLAMPTIC WOMEN
Amanda Eddins
Digitized by the Internet Archive
in 2012 with funding from
LYRASIS IVIembers and Sloan Foundation
http://archive.org/details/effectofthyroidhOOeddi
Effect of Thyroid Hormones on ATIR mRNA Levels
in HEK 293 cells: Implications for Early-Onset
Hypertension in Children Bom of Preeclamptic Women
By: Amanda Eddins
A Thesis Submitted in Partial FLilfiilnicnt of
Requirements of the CSU Honc>i-s PrograPii
For Honors in the degree of
Bachelors of Science in Biology,
College of Science.
Columbus State University
•>^ Thesis Advisor: Kathleen Sellers Ph.D 'YjlX^^^^\] X^ Date: CS/olloSC
•^ Committee Member: Brian Schwartz Ph.D ^^^^^ ]/^, ^^LSa^^a^ Date: ^—/-^^t?0
^ CSU Honors Program Director: Danna Gibson Ph.D L)|v^^ »tk <P<^t-.—Date: 5 1 '^i
^ \
Effect of Thyroid Hormones on ATIR mRNA Levels in
HEK293 cells: Implications for Early-Onset Hypertension on
Children Born of Preeclamptic Women
Mandy Eddins
Abstract:
This experiment tested the effect of thyroid hormones, T3 or T4, on angiotensin II
type 1 receptor mRNA levels in human embryonic kidney cells (HEK). Maternal
preeclampsia is a prediction of higher ambulatory blood pressure (ABP) in the exposed
offspring. The mother's blood pressure affects the blood pressure of the fetus since the
placenta mediates blood flow. Thyroid hormone can increase production of
angiotensinogen, which is a part of the renin-angiotensin system (RAS). RAS regulates
blood pressure. Hypothesis: HEK 293 cells treated with T3 and T4 will have more
angiotensin II type I receptors than those not treated with T3 and T4. Those HEK 293
cells treated with thyroid hormones along with angiotensin I will have even more
angiotensin II type I receptors than those just treated with thyroid hormones. The
HEK293 cells were treated with Ts+Ang I, T3, Ang I, T4+Ang I, T4, and PBS (control).
After the treated cells were collected of all three trials RNA was isolated and quantified.
After RNA quantification was performed using a spectrophotometer, RT-PCR and a gel
electrophoresis were completed. A one-way ANOVA and LSD Post-HOC test were run
using SPSS software for statistical analysis. Angiotensin I led to an increase in mRNA
levels of ATIR, which causes vasoconstriction and therefore higher blood pressure. This
increase in ATIR mRNA levels is attenuated when T3 is added.
Background:
Preeclampsia is the development of high blood pressure and proteinuria in
pregnant women after 20 weeks gestation (Cnossen 2006). Preeclampsia occurs in 5% to
7% of all pregnancies (Tenhola 2003). It's also the leading cause of premature birth
worldwide. Some risks associated with preeclampsia are maternal diabetes, persistent
high blood pressure, kidney disease, stroke, autoimmune disorders, fetal death, fetal
growth retardation, small for gestational age (SGA) size, and thrombophilias (Cnossen
2006, Walker 2000). The possible causes of preeclampsia include: poor diet, high body
fat percentage and insufficient blood flow to the uterus (Cnossen 2006). Atypical
implantation of fertilized egg and excessive placental tissue are also possible causes of
preeclampsia (Cnossen 2006). The only way to treat preeclampsia is to remove the
placenta, which cannot be done until delivery of the fetus. Prematurity often occurs with
preeclampsia because the doctor may decide delivering the baby early is best for the
mother. These are several possible causes for preeclampsia although the exact etiology
remains unknown. An important point of interest is that mothers and fetuses affected by
preeclampsia are more likely to have cardiovascular disease later in life.
Maternal preeclampsia is a prediction of higher ambulatory blood pressure (ABP)
in the exposed ofiFspring. The mother's blood pressure affects the blood pressure of the
fetus since the placenta mediates blood flow. The amount of blood the fetus gets depends
on the amount of blood that enters the placenta. Blood pressure is the force per area that
the blood exerts on the walls of the blood vessels. Systolic blood pressure is pressure on
the arteries when the ventricles of the heart are contracting. Diastolic blood pressure is
the measure of the force exerted on the blood vessels when the heart is at rest. As early
as the age of six, maternal preeclamptic children had higher diastolic blood pressures than
control subjects born to normotensive mothers (Palti 1989). Twelve-year-old children
born to preeclamptic mothers (PRE) have significantly increased 24-hour systolic and
diastolic ambulatory blood pressures than children of non-preeclamptic mothers (non-
PRE) (Tenhola 2006). PRE children had significantly higher systolic and diastolic blood
pressure values than non-PRE children, even after adjusting the values by current weight
and height (Tenhola 2003). The child's gender is also a factor is elevated ABP in PRE
children. PRE males at age 12 were shown to have a higher 24 hour systolic ABP than
PRE females of the same age (Tenhola 2006). In addition, 17-year-old females with
maternal preeclampsia had higher blood pressures than their coed controls (Seidman
1991 ). Menstruation also occurred at an earlier age in the preeclamptic group than in the
normotensive group (Vatten 2003). Systolic blood pressure was significantly higher in
the preeclamptic group than in the non-preeclamptic group (Vatten 2003). There was no
significant difference in diastolic blood pressure between the two groups (Vatten 2003).
There is a reduced risk of breast cancer in female offspring of preeclamptic pregnancies
(Vatten 2003).
The body's nervous system and hormones determine its blood pressure. The
autonomic nervous system regulates the rate of heart contractions. The vagus nerve
controls the parasympathetic nervous system that lowers the heart rate. Both the cervical
and upper ganglia regulate the sympathetic nervous system, which increases the heart
rate. The adrenal medulla exerts hormonal control via epinephrine secretion to raise the
heart rate. PRE children have sHghtly higher mean plasma epinephrine concentrations
than in non-PRE children (Tenhola 2003). SGA PRE children had the highest mean
Cortisol concentration, total cholesterol, LDL cholesterol, triglycerides, and insulin levels
than AGA (average gestational age) PRE children and non-PRE children (Tenhola 2003).
High systolic 24-hour ABP is associated with high plasma epinephrine concentrations
and being born SGA in the PRE children (Tenhola 2006).
Thyroid Hormones ' Relation to Preeclampsia
Thyroid Stimulating Hormone (TSH) is synthesized in the anterior pituitary
gland. TSH is a tropic hormone, meaning it stimulates other endocrine glands to release
hormones. Specifically, TSH stimulates the thyroid gland to absorb iodine and then
synthesize and release thyroid hormones including thyroxine and triiodothyronine.
Thyroxine (T4) and Triiodothyronine (T3) are two thyroid hormones that are
required for grovvlh and neurological development in children. T3 is the active form of
thyroid hormone and T4 is the form stored in the thyroid gland for use if T3 levels are
exhausted. However the T4 must be converted to T3 before becoming active. T3 and T4
increase the rate of cellular respiration, protein and fatty acid synthesis, and degradation
in many tissues. Both T3 and T4 have vasodilatory actions and T3 may maintain vascular
tone (Gumieniak 2005). Variations in thyroid hormone concentrations define
vasodilation and hypertension (Gumieniak 2005). TSH is positively correlated with
systolic and diastolic blood pressure levels (Fommei 2002). High levels of T4 and T3






Figure 1.Thyroid Hormone Interactions derived from "Control of Thyroid Hormone Synthesis and
Secretion" (Google Images 2007).
Thyroid Stimulating Hormone (TSH) levels are elevated in preeclamptic women
compared to normotensive women (Kumar 2005, Basbug 1999). Maternal thyroid
hormones are able to cross the placenta (Thyroid Australia LTD. 2001). Fetuses rely on
their mother's hormones for the first 12 weeks of gestation because they are unable to
produce their own (Thyroid Australia LTD. 2001). The thyroid hormones are needed for
neurological development (Thyroid Australia LTD. 2001). Even after the fetus' thyroid
gland begins functioning, the mother's thyroid hormones still cross the placenta (Thyroid
Australia LTD. 2001). Birth weights of babies born to preeclamptic mothers were
negatively correlated with TSH levels (Basbug 1999). TSH is a strong association factor
for the development of preeclampsia (Kumar 2005). The association between thyroid
hormone levels and hypertension will be explained in the following section.
Hypothyroidism is linked with elevated systemic vascular resistance and
hypertension (Gumieniak 2005). Hypothalamic-pituitary-thyroid pathway genes may be
involved in blood pressure regulation (Gumieniak 2005). Spontaneously hypertensive
rats (SHR) have high-normal TSH levels compared with normal rats. A significant
proportion of hypertensives have high-normal TSH concentrations. Normotensive
subjects who had a family history of hypertension had considerably higher serum TSH
levels than those subjects who did not have a hypertensive family history; even after age,
gender, race and free T4 index were adjusted (Gumieniak 2005). Other metabolic
systems also have an effect on blood pressure.
Thyroid hormone can increase production of angiotensinogen, which is a part of
the renin-angiotensin system (RAS) (Saladin 2004). RAS regulates long-term blood
pressure. RAS is activated when blood volume decreases or when there is a drop in
blood pressure (Saladin 2004). Renin is an enzyme released from juxtaglomerular cells
in the kidneys (Saladin 2004). Angiotensinogen is a peptide that is cleaved by renin to
convert it to angiotensin I. Angiotensin converting enzyme (ACE) converts angiotensin I
to angiotensin IT Angiotensin II causes blood pressure to rise by constricting blood
vessels (Figure 2) (Saladin 2004). Renin levels are high in fetuses and angiotensin II
levels are relatively low (Schutz 1996). From this information we know that increased
blood pressure is positively correlated with the increase in thyroid hormone production,
and that fetuses have a decreased angiotensin II production.
Figure 2. Derived from Renin Angiotensin-Aldosterone System
(Chiaventone 2007)
This experiment tested the effect of thyroid hormones on angiotensin II type 1
receptor mRNA levels in human embryonic kidney cells (HEK). I was able to determine
if T3 and T4 stimulated angiotensin II activity in cells. HEK cells were the best cells to
use in this experiment because the kidney regulates blood pressure, and they are extracted
from the source of interest: embryos. Knowing how thyroid hormones effects
angiotensin I levels in HEK cells helped me determine if elevated T3 and T4 is the cause
of early onset hypertension in children born of preeclamptic mothers. Hypothesis: HEK
293 cells treated with T3 and T4 will have more angiotensin II type I receptors than those
not treated with T3 and T4. Those HEK 293 cells treated with thyroid hormones along
with angiotensin 1 will have even more angiotensin II type I receptors than those just
treated with thyroid hormones.
Methods:
Cell Cultures:
Human Embryonic Kidney (HEK) cells from cell Hne 293 were used in this
experiment.
Dulbecco's Modified Eagle's Medium was used to grow the HEK 293 cells.
Medium contained 2mM L-glutamine and Earle's BSS adjusted to contain 1.5 g/L of
sodium bicarbonate, 0. 1 mM non-essential amino acids, and 1.0 mM sodium pyruvate,
90%; heat inactivated fetal bovine serum (FBS), 10% and 1% streptomycin/ampicillin
antibiotics (ATCC 2007). Cells were maintained in an incubator at 37°C and 5% CO2
levels (ATCC 2007). All cell culture procedures were performed in a laminar flow hood.
Media was changed every 2 to 3 days (ATCC 2007).
Cell Culture Maintenance
HEK-293 cells were grown in 10 ml T-75 flasks. Once confluent, 5 ml of
trypsin was added. Trypsin caused the cells to come off the bottom of the flask.
Collected cells were added to 1 5 ml conical tubes containing 10 ml of media. This
mixture was centrifiiged at 20 rpm for 3 minutes. All supernatant liquid was removed
and the cells were resuspended in 3 ml of media. 2 ml of cells from each passage were
stored in liquid nitrogen. Then 31 ml of media was added to the remained 1 ml of cells in
the 15 ml conical vial. 10 ml was added to each of the two new T-75 flasks and 12 ml
was added to the six-well plate (2 ml per well).
Six-well plates containing HEK 293 cells plus the necessary hormones were used
for this experiment (Figure 3). Each well plate was treated as follows once it is 75-90%
confluent. Well I was treated with 100|j.l of 2 |j.M angiotensin I and 100|li1 of 43 nM T3
(Papathanasiou 2007). Well II was treated with 100^1 of 43 nM T3 and 100|j1 of PBS
(Papathanasiou 2007). Well III was treated with 100|j,l of 2 |j,M angiotensin I
(Papathanasiou 2007). Well IV was treated with 100|al of 2.26 ^M T4 and 100|j1 of 2 |liM
angiotensin I (Papathanasiou 2007). Well V was treated with 100)^1 of 2.26 ^iM T4and
100|il ofPBS (Papathanasiou 2007). Well VI served as a control and was treated with
200^1 phosphate buffered saline (PBS). Angiotensin I was added to ensure that
angiotensin II is produced. The concentrations of thyroid hormones and angiotensin I are
based on the average ranges in humans. Each treatment lasted for 24 hours. Three trials
were completed.
Figure 3. Six Well Plate
RNA isolation from cultured cells:
Isolation ofRNA was performed as described in Qiagen RNA miniprep kit
(Figure 4) (Qiagen 2006). Cells were grown in T-75 flasks then trypsinized and collected
as a cell pellet (Qiagen 2006). Adding Buffer RLT lysed the cells (Qiagen 2006). The
RNA was bound to the spin column (Qiagen 2006). The column was washed two times













Figure 4. QIAprep Miniprep Handbook (Qiagen 2006)
RNA quantification:
A spectrophotometer will be used to measure the absorbance values of RNA at
260nm and 280nm. 260nm is when the RNA can be detected and 280nm is measured to
determine purity. The expected absorbance26o/280 ratio values are 1.8-2.0.
Reverese Transcriptase- PCR
I will run reverse transcription-polymerase chain reaction analysis on the RNA
fragment using Superscript^'^ 111 First-Strand Synthesis System for RT-PCR by
Invitrogen. A cDNA Synthesis Mix will be prepared according to Invitrogen. Then 10
|il ofcDNA Synthesis Mix will be added to each RNA mixture (Invitrogen 2003). The
PCR was run at 94°C (denature proteins) for 30 seconds, 56°C for one minute, and 72°C
(amplification) for one minute. Forty-five cycles were run.
Gel Electrophoresis
Gel electrophoresis will be run on the RNA. The gel that was used for the
electrophoresis will be 1% agarose gel with Ethidium bromide added. There was a lane
for each of the six treatments from all three trials, a lane for the ladder, and a positive and
negative control lane on the gel. The experimental (ATIR) gel will show the messenger
RNA levels of Angiotensin II type I receptor. A primer pair for AT2-receptor with the
genetic sequence; sense 5'-TTCCCTTCCATGTTCTGACC-3 , antisense 5 -
AAACACACTGCGGAGCTTCT-3' will detect Angiotensin II type I receptor (Tone
2007). Angiotensin II Type I receptor consists of 532 base pairs (Li 1999). Beta-actin
messenger RNA levels will be used for the control gel. The forward primer pair for P-
actin is TCGAATTCTGGAGAAGAGCTATGAGCTGCCG and the reverse primer pair
is TCGGTACCGTGCCACCAGACAGCACTGTGTTG (Invitrogen 2007). The size of
P-actin is 201 base pairs (Li 1999). The gels were run at 120V. The experimental gel ran
for 2.5 hours and the P-actin gel ran for 4 hours and 45 minutes. Normally the gels
would only need to be run for about 1.5 hours, but the machine kept shorting out and
resetting the vohage at 20V instead of 1 20V. The films for the gels were scanned into
Adobe Photoshop so that the band densities between the experimental gel and the control
gel could be compared. The bands were compared to a positive and negative control.
Statistical analysis:
A one-way ANOVA was performed to determine if the different treatments of
angiotensin 1 and thyroid hormones had different affects on the HEK293 cells. An LSD
Post-HOC test was also performed to determine where the significant differences lie.
The ratios of band densities between the Angiotensin II type I receptor gel and the P-actin
gel were compared for each of the five different treatments. An average ratio for each
treatment was taken from the three trials. A standard deviation was used to measure the
possibility of error in each trial.
Results:
Angiotensin I (Ang I) increased mRNA levels of Angiotensin TI type 1 receptors
(ATIR). ATIR mRNA levels in HEK293 cells treated with Ang I were significantly
(p<0.05) higher than all other treatments except T3 (Figures 6 & 7).
Figure 5. ATIR gel (left) and Beta-actin gel (right). Lanes from
L-R in both images- Trial 1 Ts+Ang I, T3, Ang I, T4+Ang I, T4,
control; Trial 2 Tj+Ang I, T3, Ang I, LADDER, T4+Ang I, T4,
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Figure 6. Mean ATIR mRNA levels normalized to B-actin of three trials.
Multiple Comparisons





(1) Treatnnent (J) Treatment (l-J) Std. Error Sig, Upper Bound Lower Bound
1.00 2.00 -.16090 .175662 ,378 -.54363 ,22184
3.00 -.51966(*) .175662 .012 -.90239 -,13692
4.00 -.06619 .175662 .713 -.44892 ,31655
5.00 .18778 .175662 .306 -.19496 ,57051
6,00 -.04397 .175662 .807 -.42670 ,33877
2.00 1.00 .16090 .175662 .378 -.22184 ,54363
3.00 -.35876 .175662 .064 -.74149 ,02397
4.00 .09471 .175662 .600 -.28802 ,47745
5.00 .34868 .175662 .070 -.03406 ,73141
6.00 .11693 .175662 .518 -.26580 ,49966
3.00 1.00 .51966r) .175662 .012 .13692 ,90239
2.00 .35876 .175662 .064 -.02397 ,74149
4.00 .45347(*) .175662 .024 .07074 ,83621
5.00 .70744(*) .175662 .002 .32470 1,09017
6.00 .47569(*) .175662 .019 .09296 ,85842
4.00 1.00 .06619 .175662 .713 -.31655 ,44892
2.00 -.09471 .175662 .600 -47745 ,28802
3.00 -.45347(*) .175662 .024 -.83621 -07074
5.00 .25396 .175662 .174 -.12877 ,63670
6.00 .02222 .175662 .901 -.36052 ,40495
5.00 1.00 -.18778 .175662 .306 -.57051 ,19496
2.00 -.34868 .175662 .070 -.73141 ,03406












































Based on observed means.
• The mean difference is significant at the .05 level.
Figure 7. LSD Post-HOC table from one-way ANOVA. Treatment 1= T3+Ang I,
Treatment 2= T3, Treatment 3= Ang 1, Treatment 4= T4+ Ang I, Treatment 5= T4,
Treatment 6= Control (PBS)
Discussion:
Given these results both of my hypotheses must be rejected. HEK293 cells
treated with thyroid hormones did not have significantly higher levels ofAT 1R than
those not treated with thyroid hormones. This could be because thyroid hormones
increase metabolism and therefore cause more ATP to be made. The increase in ATP
production may have distracted the cells from making more ATIR. HEK293 cells treated
with both thyroid hormones and angiotensin I also did not have more ATIR than those
only treated with thyroid hormones. In fact, cells treated with both T3 and Ang I had
lower mRNA levels ofATIR than those treated with just T3. It seemed that T3 had an
inhibiting effect on Ang I activity. Cells treated with T4 and Ang I did have higher levels
ofATIR mRNA than cells treated with only T4. This could be because T4 is the inactive
thyroid hormone and therefore did not inhibit Ang I activity.
Angiotensin I led to an increase in mRNA levels of ATIR, which causes
vasoconstriction and therefore increased blood pressure. This increase in ATIR is
attenuated when T3 is added.
Increased TSH leads to an increase in thyroid hormone production which leads to
an increase in angiotensinogen. Women with preeclampsia are known to have increased
TSH levels. Renin levels are known to be high in fetuses, so renin would cleave the
angiotensinogen into Ang I (Schutz 1996). Since fetuses begin producing their own
hormones at 12 weeks gestation (Thyroid Australia LTD. 2001), the HEK293 cells
should have angiotensin-converting enzyme needed to convert the Ang I into angiotensin
n.
Further studies need to be conducted on this topic. An arterial (endothelial) cell
line could be used in place ofHEK293 cells to see if the results are similar to what I
found in this experiment. Adding the thyroid hormone treatments a day before adding
the angiotensin I treatment could determine if T3 actually does have an inhibiting effect
on Ang 1. One other research idea would be to measure the mRNA levels of angiotensin
II type 2 receptor. This receptor causes vasodilation instead of vasoconstriction, so the
results may be opposite of what was found in this study.
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